BioMarin Pharmaceutical (BMRN) Stock Price Target 2026

The average analyst price target for BioMarin Pharmaceutical is $88.64, 54.8% above the current price. Of 28 analysts, 20 rate it Buy and 8 Hold. Targets range from $60 to $126. The latest change came on Nov 4, 2026, when JP Morgan lowered its price target on BioMarin Pharmaceutical from $87 to $86 and kept an Overweight rating.

The Average Analyst Price Target for BioMarin Pharmaceutical is $88.64.

Price Target Range — 10 Quarters

Analyst Consensus — 28 Analysts

20Buy

8Hold

Consensus RatingBuy# Analysts28Avg. Consensus PT$88.64Upside to Avg. PT+54.8%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for BioMarin Pharmaceutical Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 4, 2026	JP Morgan	Jessica Fye	PT Cut	Overweight	$87→$86
Nov 3, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$122→$119
Nov 3, 2026	Oppenheimer	Leland Gershell	PT Cut	Outperform	$97→$94
Nov 3, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	$60
Nov 3, 2026	RBC Capital	Luca Issi	PT Cut	Sector Perform	$62→$60
Nov 3, 2026	Stifel	Paul Matteis	PT Cut	Hold	$70→$66
Oct 21, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$124→$122
Oct 20, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$86→$87
Oct 20, 2026	Cantor Fitzgerald	Olivia Brayer Saunders	Maintained	Overweight	$86
Oct 15, 2026	UBS	Joon Lee	Assumes	Buy	$114→$88
Oct 14, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$111→$114
Sep 10, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	$60
Sep 1, 2026	Piper Sandler	Allison Bratzel	PT Raise	Overweight	$88→$90
Aug 31, 2026	Jefferies	Akash Tewari	PT Raise	Buy	$104→$105
Aug 31, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Neutral	$59→$60
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Outperform	$98
Aug 18, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Neutral	$60→$59
Aug 17, 2026	Piper Sandler	Allison Bratzel	PT Raise	Overweight	$82→$88
Aug 17, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$105→$111
Aug 10, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$111→$114

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $86

JP Morgan analyst Jessica Fye maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $87 to $86.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $119

Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $122 to $119.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $94

Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and lowers the price target from $97 to $94.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and maintains $60 price target.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $60

RBC Capital analyst Luca Issi maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price target from $62 to $60.

Benzinga Newsdesk

PRO
Stifel Maintains Hold on BioMarin Pharmaceutical, Lowers Price Target to $66

Stifel analyst Paul Matteis maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Hold and lowers the price target from $70 to $66.

Benzinga Newsdesk

BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical (BMRN) Stock Price Target 2026

The Average Analyst Price Target for BioMarin Pharmaceutical is $88.64.

Latest Upgrades and Downgrades for BioMarin Pharmaceutical Stock

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $86

PRO
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $119

PRO
Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $94

PRO
HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target

PRO
RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $60

PRO
Stifel Maintains Hold on BioMarin Pharmaceutical, Lowers Price Target to $66

People Also Watch

People Also Watch

BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical (BMRN) Stock Price Target 2026

The Average Analyst Price Target for BioMarin Pharmaceutical is $88.64.

Latest Upgrades and Downgrades for BioMarin Pharmaceutical Stock

Analyst Ratings News

PROJP Morgan Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $86

PROMorgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $119

PROOppenheimer Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $94

PROHC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target

PRORBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $60

PROStifel Maintains Hold on BioMarin Pharmaceutical, Lowers Price Target to $66

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $86

PRO
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $119

PRO
Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $94

PRO
HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target

PRO
RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $60

PRO
Stifel Maintains Hold on BioMarin Pharmaceutical, Lowers Price Target to $66